

June 24, 2025

The Honorable Jamieson Greer Ambassador U.S. Trade Representative 600 17th Street NW Washington, DC 20508

Dear Ambassador Greer,

As the President & CEO of RetireSafe, a group that advocates on behalf of America's seniors, I am writing today to highlight the negative impacts of a Most Favored Nation (MFN) prescription drug pricing policy on senior patients. As you implement President Trump's Executive Order, *Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients*, we urge the administration to reconsider implementing this policy.

MFN indexes American pharmaceutical prices to those in other nations, such as Canada and European countries – countries that embrace socialized medicine. Their single-payer healthcare systems couldn't be fundamentally more different than the United States. While they boast lower list prices, it is only because they use discriminatory measures like the Quality Adjusted Life Year (QALY) that devalue care for older, sicker patients. America, on the other hand, has prioritized helping those vulnerable or sick patients in desperate need of care. Implementing MFN and essentially importing these pricing policies to save costs would leave those patients behind—which is not a policy that benefits American seniors.

Likewise, MFN will reduce access to treatments and medications in the U.S. by undermining the key incentive for their creation. By limiting the ability for innovators to be certain they'll be able to recoup returns on the large investments that go into creating new products and bringing them to pharmacy shelves, MFN disincentivizes development. Every new drug that is not brought to market due to government-imposed policies could be a life-extending or saving treatment for a senior in need.

Seniors rely on medications more than any other age demographic. This means that, when access is on the line, they have the most to lose. Our aging population deserves government policies that will protect their medications and treatments, not threaten them.

I urge you to keep America's seniors top of mind and not implement this policy. Adopting foreign pricing models that deprioritize vulnerable patients is not the answer to foreign freeloading.

Sincerely,

Mark Gibbons President & CEO RetireSafe